# AC Immune SA > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/AC Immune SA). ## Overview AC Immune SA is a clinical-stage biopharmaceutical company based in Switzerland that develops medicines and diagnostics for neurodegenerative diseases driven by misfolded proteins. Its work centers on two proprietary platforms, SupraAntigen® and Morphomer®, which it uses to build therapeutic and diagnostic programs for Alzheimer’s disease, Parkinson’s disease, ALS and related indications. ## Products & services • Therapeutic antibodies for misfolded protein targets • Small-molecule programs built on the Morphomer® platform • Precision-diagnostic PET tracers for neurodegeneration • Partnered discovery and licensing programs • Preclinical and clinical-stage pipeline assets - **Therapeutics - Antibody Programs** (45%) — Conformation-specific biologics designed to prevent or treat neurodegenerative disease biology. - **Therapeutics - Small Molecules** (20%) — Morphomer-based small-molecule candidates aimed at misfolded protein targets. - **Diagnostics** (15%) — PET and related diagnostic programs intended to detect neurodegenerative pathology. - **Collaborations and Licenses** (20%) — Upfronts, milestones and royalties from partnered development programs. - Therapeutic antibodies for misfolded protein targets - Small-molecule programs built on the Morphomer® platform - Precision-diagnostic PET tracers for neurodegeneration - Partnered discovery and licensing programs - Preclinical and clinical-stage pipeline assets ## Customers AC Immune’s direct customers are primarily large pharmaceutical partners that license programs, fund development, and may commercialize approved assets. Its end users are patients, clinicians and healthcare systems in neurology and neurodegeneration, where diagnostic clarity and disease-modifying therapies are needed. The company also serves research-oriented collaborators that support platform validation and pipeline advancement. - **Pharmaceutical licensing partners** (primary) — Buy access to discovery programs, development rights and potential commercial rights for lead assets. - **Neurology patients and prescribers** (primary) — Use eventual approved therapies and diagnostics in Alzheimer’s, Parkinson’s and related diseases. - **Healthcare imaging providers** (secondary) — Use PET tracers and diagnostic tools to identify pathology and support precision medicine. - **Academic and research collaborators** (secondary) — Support preclinical validation, translational work and biomarker development. - Global pharma partners that fund and license programs - Neurology patients needing disease-modifying options - Hospitals and imaging centers using diagnostic tracers - Clinicians managing Alzheimer’s, Parkinson’s and ALS - Research collaborators validating targets and platforms ## Geography AC Immune is headquartered in Lausanne, Switzerland and operates through a Swiss parent company with a U.S. subsidiary in Delaware. Its business is global in nature because partnerships, clinical development and intellectual property exploitation span North America, Europe and other major pharmaceutical markets. - Headquartered in Lausanne, Switzerland - Operates through AC Immune SA and AC Immune USA, Inc. - Partnerships and licensing are global rather than country-specific - Clinical and research activity depends on major pharma markets - Funds are held mainly in CHF, EUR and USD ## Strategy The company’s strategy is built around a three-pillar model: Alzheimer’s disease, other neurodegenerative diseases such as Parkinson’s and ALS, and diagnostics. It seeks to turn proprietary platform science into partnered and proprietary programs that can attract non-dilutive funding, milestones and royalties while preserving optionality across multiple disease targets. - **Advance platform-derived pipeline candidates** (short-term) — Clinical validation is the main path to value creation for a platform biopharma company. - **Expand partnering and licensing income** (medium-term) — Upfronts, milestones and royalties reduce funding needs and diversify risk. - **Broaden beyond Alzheimer’s disease** (medium-term) — Multiple indications increase the usable addressable market and platform relevance. - **Develop precision diagnostics** (long-term) — Diagnostics can improve patient selection and support commercialization of therapies. - Advance Alzheimer’s, non-AD NDD and diagnostics as three core pillars - Use SupraAntigen® and Morphomer® as repeatable discovery engines - Partner selective programs to secure non-dilutive funding - Progress Phase 2 and Phase 3 assets toward clinical validation - Build precision-medicine diagnostics alongside therapeutics ## Risks AC Immune depends on successful clinical development, regulatory clearance and partner execution, all of which are uncertain in neurodegenerative disease. Its revenue model is exposed to collaboration timing and milestone concentration, while its R&D-heavy structure makes capital allocation, trial outcomes and impairment judgments especially important. - **Clinical development failure** [critical] — Pipeline value depends on proof of mechanism and clinical efficacy in difficult neurodegenerative diseases. - **Partner concentration and milestone dependence** [high] — A meaningful part of value creation comes from collaboration agreements and milestone payments. - **Regulatory and trial timeline delays** [high] — Drug and diagnostic approvals require multi-stage testing and agency review. - **Impairment of IPR&D assets** [medium] — Capitalized intangibles and development assets can be written down if programs underperform. - **Funding and dilution risk** [high] — A clinical-stage biotech typically relies on external capital before product sales emerge. - Clinical trials may fail or show limited efficacy in high-risk indications - Partner milestones and royalties depend on third-party decisions - R&D spending is concentrated in long-duration, uncertain programs - Regulatory review of diagnostics and therapies can delay commercialization - IPR&D and other intangible assets may face impairment if programs weaken ## Accounting The most important accounting judgments relate to revenue recognition on collaboration and licensing agreements, where upfronts, milestones and other deliverables may be recognized at different times. Clinical development accruals, share-based compensation, lease liabilities, and the IPR&D asset can also materially affect reported results because they rely on estimates about timing, trial progress and asset recoverability. - **Revenue recognition for collaborations** — Can cause uneven reported revenue - **Clinical development accruals** — Can shift expense recognition across periods - **IPR&D asset impairment** — Can create large non-cash charges if programs weaken - **Share-based compensation** — Affects operating expenses and equity - **Lease accounting** — Impacts balance sheet leverage and expense profile - Collaboration revenue depends on contract terms and performance obligations - Milestone timing can create lumpy revenue recognition - Clinical accruals rely on estimates of trial work completed - IPR&D and other intangibles may require impairment testing - Share-based compensation and leases affect operating expense and liabilities --- *Last updated: 2026-09-28T11:57:27.757765+00:00*